Jordan headquartered MS Pharma has announced that Olayan Financing Company (OFC) has made a minority equity investment in the company. This partnership brings strategic depth to MS Pharma's next phase of growth, underscoring its commitment to innovation, regional expansion, and long-term value creation.
It also marks the beginning of a long-term partnership between OFC and MS Pharma's existing majority shareholders, who have distinguished themselves through decades of leadership and excellence in the pharmaceutical sector.
The transaction involves MS Pharma issuing new share capital in exchange for a substantial cash investment from OFC, resulting in OFC acquiring a minority stake in the company.
The partnership builds on MS Pharma's leadership in biosimilars, particularly in Kingdom of Saudi Arabia (KSA), where its biologics site became the first in the Kingdom to receive SFDA GMP approval for biologics manufacturing. This year, the company also plans to become the first supplier of locally manufactured biologics to the Saudi market.
These milestones reinforce the company's commitment to localisation under the Saudi National Biotechnology Strategy and Vision 2030. MS Pharma also aims to deepen collaboration with global development and licensing partners, offering its manufacturing capabilities to support export into global markets.
